Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind study of ONO-8577 vs solifenacin succinate + mirabegron in overactive bladder
jRCT2080223480Phase 2
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ONO-8577 in overactive bladder (OAB) (2 arms), sponsored by Ono Pharmaceutical.
02
Drugs
ONO-8577
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCT2080223480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223480.